{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:44:15Z","timestamp":1781581455144,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.atherosclerosis.2025.119145","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:35:08Z","timestamp":1740098108000},"page":"119145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS"],"prefix":"10.1016","volume":"403","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4317","authenticated-orcid":false,"given":"Masashi","family":"Fujino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Butters Bhsc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hucko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Psaltis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-4368","authenticated-orcid":false,"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.119145_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib2","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","article-title":"Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol","volume":"55","author":"Bayturan","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4065\/mcp.2009.0517","article-title":"Using apolipoprotein B to manage dyslipidemic patients: time for a change?","volume":"85","author":"Harper","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/eurheartj\/eht484","article-title":"In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study","volume":"35","author":"Cheng","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib7","article-title":"The causal-benefit model to prevent cardiovascular events","volume":"3","author":"Kohli-Lynch","year":"2024","journal-title":"JACC (J. Am. Coll. Cardiol.): Advances"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJM199705013361802","article-title":"Coronary risk factors and plaque morphology in men with coronary disease who died suddenly","volume":"336","author":"Burke","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/ATVBAHA.108.179739","article-title":"Concept of vulnerable\/unstable plaque","volume":"30","author":"Finn","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/eurheartj\/ehz520","article-title":"Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study","volume":"41","author":"Prati","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib13","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2005.01.054","article-title":"Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction","volume":"45","author":"Mauriello","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib15","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2009.07.078","article-title":"The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization","volume":"55","author":"Kubo","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib16","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the national lipid association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib17","doi-asserted-by":"crossref","first-page":"5M","DOI":"10.1016\/S0002-9149(98)00591-8","article-title":"Clinical trial endpoints: angiograms, events, and plaque instability","volume":"82","author":"Ballantyne","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib18","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIRCULATIONAHA.108.773747","article-title":"Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden","volume":"117","author":"Ballantyne","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib20","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib21","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"Hiro","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib24","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.jacc.2017.03.556","article-title":"Clinical significance of lipid-rich plaque detected by optical coherence tomography: a 4-year follow-up study","volume":"69","author":"Xing","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib25","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study","volume":"64","author":"Komukai","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12944-021-01528-3","article-title":"Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography","volume":"20","author":"Gao","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.amjcard.2013.10.038","article-title":"Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe","volume":"113","author":"Habara","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-023-07511-7","article-title":"Effect of intensive lipid-lowering therapy on coronary plaque stabilization derived from optical coherence tomography: a meta-analysis and meta-regression","volume":"39","author":"Liu","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib30","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib31","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","article-title":"Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events","volume":"129","author":"Mora","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib36","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/2047487319871733","article-title":"Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.119145_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstrom","year":"2022","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:47:14Z","timestamp":1746078434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"alternative-id":["S0021915025000425"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119145","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119145"}}